Hepatitis C virus infection and tight junction proteins: The ties that bind
Publication date: Available online 5 April 2020Source: Biochimica et Biophysica Acta (BBA) - BiomembranesAuthor(s): Laurent Mailly, Thomas F. Baumert
We examined whether Mac-2-binding protein glycosylation isomer (M2BPGi) levels could be a predictive marker for the presence of esophagogastric varices (EGV) in cirrhotic patients after hepatitis C virus (HCV) eradication with direct-acting antivirals (DAAs). PATIENTS AND METHODS: A total of 102 cirrhotic patients with HCV infection treated with DAAs were enrolled. Esophagogastroduodenoscopy was performed in 84 of the patients before treatment (Cohort A), in 66 after treatment (Cohort B), and in 48 at both time points (Cohort C). We examined factors associated with EGV before and after DAA treatment. RESULTS: In Co...
ConclusionThe mini-tablet combination of OBV, PTV, ritonavir, and DSV plus ribavirin to treat HCV GT1a infection for 12 weeks was highly effective and suitable in children 3–11 years of age.Trial RegistrationClinicalTrials.gov identifier, NCT02486406.
With a worldwide prevalence of 15.4%, hepatitis C virus (HCV) has been estimated to be the most prevalent major infectious disease in prisons. The exceptionally high prevalence of HCV in prisons is attributabl...
Authors: Schauer C, Mules T, Rijnsoever MV, Gane E Abstract BACKGROUND: Regular surveillance for hepatocellular carcinoma (HCC) in patients with chronic hepatitis B viral (HBV) infection and hepatitis C (HCV) cirrhosis improves survival by earlier detection of the cancer at an earlier stage when curative intervention may still be possible. We compared patient characteristics, surveillance history and outcomes in patients presenting with advanced HCC secondary to HBV and HCV. METHOD: In this retrospective study, clinical databases and notes were reviewed in all cases of advanced HCC related to HBV or HCV referre...
Donor scarcity, the principal challenge of kidney allocation today, is a result of the success of our field. Over recent decades, we have accomplished dramatic improvements in immunosuppression, perioperative care, and approaches to patient selection. As a result, successful kidney transplantation is all but taken for granted. Consequently, the demand for kidneys continues to far outpace the supply of donated organs. One strategy has been to re-examine how best to use organ categories that were previously thought to be marginal or unusable, such as those from donors infected with hepatitis C virus (HCV).
This report highlights the epidemic of hepatitis C among US adults, and supports CDC's new screening recommendations to screen all adults for this curable disease.Morbidity &Mortality Weekly Report
No abstract available
Conclusions. Older NASH patients (≥65) have an increased risk of waitlist and posttransplant mortality compared to younger individuals, although outcomes were similar to patients with ALD or HCV of corresponding age. These individuals should be carefully evaluated prior to LT, considering their functional status, renal function, and cardiovascular risk. Further studies are needed to optimize outcomes in this growing population of transplant candidates.
Conclusions. In the modern direct-acting antiviral era, calculated likely KDPI overestimates risk kidneys from HCV (+) donors. Donor viremia conveys an early risk which appears to subside over time. These results suggest that it may be time to revise the kidney donor risk index.
Conclusions. Our findings suggest that ATG, as compared to IL2RA, may lower the risk of acute rejection without increasing hepatic complications in HCV+ KT recipients. Given the higher rates of acute rejection in this population, ATG appears to be safe and reasonable for HCV+ recipients.